Professor | Yunlu Jia | Asia Growth Partners

	Upload Avatar (500 x 500)
Name	Yunlu Jia
Contact Information	jiayunlu@zju.edu.cn
Language ability	Chinese, English
Province	Zhejiang

Upload Avatar (500 x 500)

Name

Yunlu Jia

Contact Information

jiayunlu@zju.edu.cn

Language ability

Chinese, English

Province

Zhejiang

University/Lab Affiliation and Title	Zhejiang University
Faculty	Medical
Academic Background & Achievements	Ph.D. in Oncology: Zhejiang University Postdoctoral Research in Oncology: National University of Singapore Published over 20 SCI papers in international journals such as Cancer Research, Blood Cancer Journal, Journal of Hematology and Oncology
Work Experience	2022-12 to present - Zhejiang University School of Medicine First Affiliated Hospital - Specially Appointed Researcher 2020-12 to present - Zhejiang University School of Medicine First Affiliated Hospital - Attending Physician, Department of Oncology 2020-01 to 2020-12 - Zhejiang University School of Medicine First Affiliated Hospital - Physician, Department of Oncology 2017-11 to 2019-11 - National University of Singapore School of Medicine - Joint Ph.D. Training Program, Funded by China Scholarship Council, Co-supervisor: Chng Wee Joo 2013-10 to 2014-10 - Sun Yat-sen University Cancer Prevention and Treatment Center - Joint Training, Co-supervisor: Deng Wuguo

University/Lab Affiliation and Title

Zhejiang University

Faculty

Medical

Academic Background & Achievements

Ph.D. in Oncology: Zhejiang University
Postdoctoral Research in Oncology: National University of Singapore
Published over 20 SCI papers in international journals such as Cancer Research, Blood Cancer Journal, Journal of Hematology and Oncology

Work Experience

2022-12 to present - Zhejiang University School of Medicine First Affiliated Hospital - Specially Appointed Researcher
2020-12 to present - Zhejiang University School of Medicine First Affiliated Hospital - Attending Physician, Department of Oncology
2020-01 to 2020-12 - Zhejiang University School of Medicine First Affiliated Hospital - Physician, Department of Oncology
2017-11 to 2019-11 - National University of Singapore School of Medicine - Joint Ph.D. Training Program, Funded by China Scholarship Council, Co-supervisor: Chng Wee Joo
2013-10 to 2014-10 - Sun Yat-sen University Cancer Prevention and Treatment Center - Joint Training, Co-supervisor: Deng Wuguo

Areas of Focus	Application of high-throughput genomics and proteomics technologies to identify new diagnostic subtypes, prognostic factors, and therapeutic targets in solid tumor samples and cell models
Publications	Super Enhancer-Mediated Upregulation of HJURP Promotes Growth and Survival of t(4;14)-Positive Multiple Myeloma, Jia Y, Zhou J, Tan TK, Chung TH, Chen Y, Chooi JY, Sanda T, Fullwood MJ, Xiong S, Toh SHM, Balan K, Wong RWJ, Lim JSL, Zhang E, Cai Z, Shen P, Chng WJ, 2022 Myeloma-specific superenhancers affect genes of biological and clinical relevance in myeloma, Jia Y, Zhou J, Tan TK, Chung TH, Wong RWJ, Chooi JY, Lim JSL, Sanda T, Ooi M, De Mel S, Soekojo C, Chen Y, Zhang E, Cai Z, Shen P, Ruan J, Chng WJ, 2021 Super-enhancers: critical roles and therapeutic targets in hematologic malignancies, Jia Y, Chng WJ, Zhou J, 2019 HJURP regulates cell proliferation and chemo-resistance via YAP1/NDRG1 transcriptional axis in triple-negative breast cancer, Mao M, Jia Y, Chen Y, Yang J, Xu L, Zhang X, Zhou J, Li Z, Chen C, Ju S, Wang L, 2022 Cancer cell membrane-wrapped nanoparticles for cancer immunotherapy: A review of current developments, Jiang Q, Xie M, Chen R, Yan F, Ye C, Li Q, Xu S, Wu W, Jia Y#, Shen P#, Ruan J#, 2022 Immunotherapy of cholangiocarcinoma: Therapeutic strategies and predictive biomarkers, Chen R, Zheng D, Li Q, Xu S, Ye C, Jiang Q, Yan F, Jia Y#, Zhang X#, Ruan J#, 2022 Sporoderm-Broken Spores of Ganoderma lucidum Sensitizes Ovarian Cancer to Cisplatin by ROS/ERK Signaling and Attenuates Chemotherapy-Related Toxicity, Cen K, Chen M, He Mengye, Li Zhenhao, Song Yinjing, Liu Pu, Jiang Qi, Xu Suzhen, Jia Y#, Shen Peng#, 2022 PLAC8 promotes adriamycin resistance via blocking autophagy in breast cancer, Chen Y, Jia Y, Mao M, Gu Y, Xu C, Yang J, Hu W, Shen J, Hu D, Chen C, Li Z, 2021 PLCA8 suppresses breast cancer apoptosis by activating the PI3k/AKT/NF‐κB pathway, Mao M, Chen Y, Jia Y, Yang J, Wei Q, Li Z, Chen L, Chen C, Wang L, 2019 The novel KLF4/PLAC8 signaling pathway regulates lung cancer growth, Jia Y, Ying X, Zhou J, Chen Y, Luo X, Xie S, Wang QC, Hu W, Wang L, 2018 KLF4 overcomes tamoxifen resistance by suppressing MAPK signaling pathway and predicts good prognosis in breast cancer, Jia Y, Zhou J, Luo X, Chen M, Chen Y, Wang J, Xiong H, Ying X, Hu W, Zhao W, Deng W, Wang L, 2018 Exosome: emerging biomarker in breast cancer, Jia Y, Chen Y, Wang Q, et al., 2017 KLF4 downregulates hTERT expression and telomerase activity to inhibit lung carcinoma growth, Hu W, Jia Y*, Xiao X, Lv K, Chen Y, Wang L, Luo X, Liu T, Li W, Li Y, Zhang C, Yu Z, Huang W, Sun B, Deng WG, 2016 Superenhancer profiling of multiple myeloma in search of novel oncogenes and therapeutic targets, Jia Y, et al., 2019 The signal pathway of Lin28 and tumor, Jia Y, L. V. Kezhen, Na Lin, and H. U. Wenxian, 2014

Areas of Focus

Application of high-throughput genomics and proteomics technologies to identify new diagnostic subtypes, prognostic factors, and therapeutic targets in solid tumor samples and cell models

Publications

Super Enhancer-Mediated Upregulation of HJURP Promotes Growth and Survival of t(4;14)-Positive Multiple Myeloma, Jia Y, Zhou J, Tan TK, Chung TH, Chen Y, Chooi JY, Sanda T, Fullwood MJ, Xiong S, Toh SHM, Balan K, Wong RWJ, Lim JSL, Zhang E, Cai Z, Shen P, Chng WJ, 2022
Myeloma-specific superenhancers affect genes of biological and clinical relevance in myeloma, Jia Y*, Zhou J*, Tan TK*, Chung TH, Wong RWJ, Chooi JY, Lim JSL, Sanda T, Ooi M, De Mel S, Soekojo C, Chen Y, Zhang E, Cai Z, Shen P, Ruan J, Chng WJ, 2021
Super-enhancers: critical roles and therapeutic targets in hematologic malignancies, Jia Y, Chng WJ, Zhou J, 2019
HJURP regulates cell proliferation and chemo-resistance via YAP1/NDRG1 transcriptional axis in triple-negative breast cancer, Mao M*, Jia Y*, Chen Y, Yang J, Xu L, Zhang X, Zhou J, Li Z, Chen C, Ju S, Wang L, 2022
Cancer cell membrane-wrapped nanoparticles for cancer immunotherapy: A review of current developments, Jiang Q, Xie M, Chen R, Yan F, Ye C, Li Q, Xu S, Wu W, Jia Y#, Shen P#, Ruan J#, 2022
Immunotherapy of cholangiocarcinoma: Therapeutic strategies and predictive biomarkers, Chen R, Zheng D, Li Q, Xu S, Ye C, Jiang Q, Yan F, Jia Y#, Zhang X#, Ruan J#, 2022
Sporoderm-Broken Spores of Ganoderma lucidum Sensitizes Ovarian Cancer to Cisplatin by ROS/ERK Signaling and Attenuates Chemotherapy-Related Toxicity, Cen K, Chen M, He Mengye, Li Zhenhao, Song Yinjing, Liu Pu, Jiang Qi, Xu Suzhen, Jia Y#, Shen Peng#, 2022
PLAC8 promotes adriamycin resistance via blocking autophagy in breast cancer, Chen Y*, Jia Y*, Mao M*, Gu Y, Xu C, Yang J, Hu W, Shen J, Hu D, Chen C, Li Z, 2021
PLCA8 suppresses breast cancer apoptosis by activating the PI3k/AKT/NF‐κB pathway, Mao M*, Chen Y*, Jia Y*, Yang J, Wei Q, Li Z, Chen L, Chen C, Wang L, 2019
The novel KLF4/PLAC8 signaling pathway regulates lung cancer growth, Jia Y*, Ying X*, Zhou J*, Chen Y, Luo X, Xie S, Wang QC, Hu W, Wang L, 2018
KLF4 overcomes tamoxifen resistance by suppressing MAPK signaling pathway and predicts good prognosis in breast cancer, Jia Y*, Zhou J*, Luo X*, Chen M, Chen Y, Wang J, Xiong H, Ying X, Hu W, Zhao W, Deng W, Wang L, 2018
Exosome: emerging biomarker in breast cancer, Jia Y, Chen Y, Wang Q, et al., 2017
KLF4 downregulates hTERT expression and telomerase activity to inhibit lung carcinoma growth, Hu W*, Jia Y*, Xiao X, Lv K, Chen Y, Wang L, Luo X, Liu T, Li W, Li Y, Zhang C, Yu Z, Huang W, Sun B, Deng WG, 2016
Superenhancer profiling of multiple myeloma in search of novel oncogenes and therapeutic targets, Jia Y, et al., 2019
The signal pathway of Lin28 and tumor, Jia Y, L. V. Kezhen, Na Lin, and H. U. Wenxian, 2014

Genomics Proteomics Solid Tumors Diagnostic Subtypes Prognostic Factors Therapeutic Targets High-Throughput Cancer Research Cell Models Oncology

Chenfang Dong - Zhejiang University

Jingjing Wu - Zhejiang University

Kai Wang - Zhejiang University

View All

Personal Information

Academic Information

Research

Contact us

No account yet?

Personal Information

Academic Information

Research

Contact us